Report Detail

Service & Software Global CNS Specific Antisense Oligonucleotides Market Size, Status and Forecast 2020-2026

  • RnM4271921
  • |
  • 27 December, 2020
  • |
  • Global
  • |
  • 92 Pages
  • |
  • QYResearch
  • |
  • Service & Software

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Market Analysis by Type
    • 1.3.1 Global CNS Specific Antisense Oligonucleotides Market Size Growth Rate by Type: 2020 VS 2026
    • 1.3.2 Polyneuropathy Treatment
    • 1.3.3 Spinal Muscular Atrophy (SMA) Treatment
    • 1.3.4 Huntington’s Disease Treatment
  • 1.4 Market by Application
    • 1.4.1 Global CNS Specific Antisense Oligonucleotides Market Share by Application: 2020 VS 2026
    • 1.4.2 Hospital Pharmacies
    • 1.4.3 Retail Pharmacies
    • 1.4.4 Online Pharmacies
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global CNS Specific Antisense Oligonucleotides Market Perspective (2015-2026)
  • 2.2 CNS Specific Antisense Oligonucleotides Growth Trends by Regions
    • 2.2.1 CNS Specific Antisense Oligonucleotides Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 CNS Specific Antisense Oligonucleotides Historic Market Share by Regions (2015-2020)
    • 2.2.3 CNS Specific Antisense Oligonucleotides Forecasted Market Size by Regions (2021-2026)
  • 2.3 CNS Specific Antisense Oligonucleotides Industry Dynamic
    • 2.3.1 CNS Specific Antisense Oligonucleotides Market Trends
    • 2.3.2 CNS Specific Antisense Oligonucleotides Market Drivers
    • 2.3.3 CNS Specific Antisense Oligonucleotides Market Challenges
    • 2.3.4 CNS Specific Antisense Oligonucleotides Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top CNS Specific Antisense Oligonucleotides Players by Market Size
    • 3.1.1 Global Top CNS Specific Antisense Oligonucleotides Players by Revenue (2015-2020)
    • 3.1.2 Global CNS Specific Antisense Oligonucleotides Revenue Market Share by Players (2015-2020)
  • 3.2 Global CNS Specific Antisense Oligonucleotides Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by CNS Specific Antisense Oligonucleotides Revenue
  • 3.4 Global CNS Specific Antisense Oligonucleotides Market Concentration Ratio
    • 3.4.1 Global CNS Specific Antisense Oligonucleotides Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by CNS Specific Antisense Oligonucleotides Revenue in 2019
  • 3.5 Key Players CNS Specific Antisense Oligonucleotides Area Served
  • 3.6 Key Players CNS Specific Antisense Oligonucleotides Product Solution and Service
  • 3.7 Date of Enter into CNS Specific Antisense Oligonucleotides Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 CNS Specific Antisense Oligonucleotides Breakdown Data by Type

  • 4.1 Global CNS Specific Antisense Oligonucleotides Historic Market Size by Type (2015-2020)
  • 4.2 Global CNS Specific Antisense Oligonucleotides Forecasted Market Size by Type (2021-2026)

5 CNS Specific Antisense Oligonucleotides Breakdown Data by Application

  • 5.1 Global CNS Specific Antisense Oligonucleotides Historic Market Size by Application (2015-2020)
  • 5.2 Global CNS Specific Antisense Oligonucleotides Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America CNS Specific Antisense Oligonucleotides Market Size (2015-2026)
  • 6.2 North America CNS Specific Antisense Oligonucleotides Market Size by Type (2015-2020)
  • 6.3 North America CNS Specific Antisense Oligonucleotides Market Size by Application (2015-2020)
  • 6.4 North America CNS Specific Antisense Oligonucleotides Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe CNS Specific Antisense Oligonucleotides Market Size (2015-2026)
  • 7.2 Europe CNS Specific Antisense Oligonucleotides Market Size by Type (2015-2020)
  • 7.3 Europe CNS Specific Antisense Oligonucleotides Market Size by Application (2015-2020)
  • 7.4 Europe CNS Specific Antisense Oligonucleotides Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size (2015-2026)
  • 8.2 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size by Type (2015-2020)
  • 8.3 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size by Application (2015-2020)
  • 8.4 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia

9 Latin America

  • 9.1 Latin America CNS Specific Antisense Oligonucleotides Market Size (2015-2026)
  • 9.2 Latin America CNS Specific Antisense Oligonucleotides Market Size by Type (2015-2020)
  • 9.3 Latin America CNS Specific Antisense Oligonucleotides Market Size by Application (2015-2020)
  • 9.4 Latin America CNS Specific Antisense Oligonucleotides Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size (2015-2026)
  • 10.2 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size by Type (2015-2020)
  • 10.3 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size by Application (2015-2020)
  • 10.4 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE

11Key Players Profiles

  • 11.1 Akcea Therapeutics, Inc.
    • 11.1.1 Akcea Therapeutics, Inc. Company Details
    • 11.1.2 Akcea Therapeutics, Inc. Business Overview
    • 11.1.3 Akcea Therapeutics, Inc. CNS Specific Antisense Oligonucleotides Introduction
    • 11.1.4 Akcea Therapeutics, Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2015-2020))
    • 11.1.5 Akcea Therapeutics, Inc. Recent Development
  • 11.2 Ionis Pharmaceuticals Inc.
    • 11.2.1 Ionis Pharmaceuticals Inc. Company Details
    • 11.2.2 Ionis Pharmaceuticals Inc. Business Overview
    • 11.2.3 Ionis Pharmaceuticals Inc. CNS Specific Antisense Oligonucleotides Introduction
    • 11.2.4 Ionis Pharmaceuticals Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2015-2020)
    • 11.2.5 Ionis Pharmaceuticals Inc. Recent Development
  • 11.3 Biogen Inc.
    • 11.3.1 Biogen Inc. Company Details
    • 11.3.2 Biogen Inc. Business Overview
    • 11.3.3 Biogen Inc. CNS Specific Antisense Oligonucleotides Introduction
    • 11.3.4 Biogen Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2015-2020)
    • 11.3.5 Biogen Inc. Recent Development
  • 11.4 Sarepta Therapeutics
    • 11.4.1 Sarepta Therapeutics Company Details
    • 11.4.2 Sarepta Therapeutics Business Overview
    • 11.4.3 Sarepta Therapeutics CNS Specific Antisense Oligonucleotides Introduction
    • 11.4.4 Sarepta Therapeutics Revenue in CNS Specific Antisense Oligonucleotides Business (2015-2020)
    • 11.4.5 Sarepta Therapeutics Recent Development
  • 11.5 Wave Life Sciences Ltd.
    • 11.5.1 Wave Life Sciences Ltd. Company Details
    • 11.5.2 Wave Life Sciences Ltd. Business Overview
    • 11.5.3 Wave Life Sciences Ltd. CNS Specific Antisense Oligonucleotides Introduction
    • 11.5.4 Wave Life Sciences Ltd. Revenue in CNS Specific Antisense Oligonucleotides Business (2015-2020)
    • 11.5.5 Wave Life Sciences Ltd. Recent Development
  • 11.6 Dynacure
    • 11.6.1 Dynacure Company Details
    • 11.6.2 Dynacure Business Overview
    • 11.6.3 Dynacure CNS Specific Antisense Oligonucleotides Introduction
    • 11.6.4 Dynacure Revenue in CNS Specific Antisense Oligonucleotides Business (2015-2020)
    • 11.6.5 Dynacure Recent Development
  • 11.7 ProQR Therapeutics N.V.
    • 11.7.1 ProQR Therapeutics N.V. Company Details
    • 11.7.2 ProQR Therapeutics N.V. Business Overview
    • 11.7.3 ProQR Therapeutics N.V. CNS Specific Antisense Oligonucleotides Introduction
    • 11.7.4 ProQR Therapeutics N.V. Revenue in CNS Specific Antisense Oligonucleotides Business (2015-2020)
    • 11.7.5 ProQR Therapeutics N.V. Recent Development
  • 11.8 Stroke Therapeutic Inc.
    • 11.8.1 Stroke Therapeutic Inc. Company Details
    • 11.8.2 Stroke Therapeutic Inc. Business Overview
    • 11.8.3 Stroke Therapeutic Inc. CNS Specific Antisense Oligonucleotides Introduction
    • 11.8.4 Stroke Therapeutic Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2015-2020)
    • 11.8.5 Stroke Therapeutic Inc. Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    CNS Specific Antisense Oligonucleotides market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global CNS Specific Antisense Oligonucleotides market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Polyneuropathy Treatment
    Spinal Muscular Atrophy (SMA) Treatment
    Huntington’s Disease Treatment

    Market segment by Application, split into
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

    Based on regional and country-level analysis, the CNS Specific Antisense Oligonucleotides market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    In the competitive analysis section of the report, leading as well as prominent players of the global CNS Specific Antisense Oligonucleotides market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Akcea Therapeutics, Inc.
    Ionis Pharmaceuticals Inc.
    Biogen Inc.
    Sarepta Therapeutics
    Wave Life Sciences Ltd.
    Dynacure
    ProQR Therapeutics N.V.


    Summary:
    Get latest Market Research Reports on CNS Specific Antisense Oligonucleotides. Industry analysis & Market Report on CNS Specific Antisense Oligonucleotides is a syndicated market report, published as Global CNS Specific Antisense Oligonucleotides Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of CNS Specific Antisense Oligonucleotides market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    2,851.52
    4,277.27
    5,703.03
    3,204.28
    4,806.41
    6,408.55
    404,804.40
    607,206.60
    809,608.80
    284,756.55
    427,134.83
    569,513.10
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report